Black Rock Inc. Karuna Therapeutics, Inc. Transaction History

Black Rock Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$161.01 - $317.85 $8.45 Million - $16.7 Million	52,457 Added 2.67%	2,015,374 $638 Million
Q3 2023 Nov 13, 2023	BUY	$164.66 - $218.08 $16.2 Million - $21.4 Million	98,281 Added 5.27%	1,962,917 $332 Million
Q2 2023 Aug 11, 2023	SELL	$176.32 - $240.22 $107 Million - $145 Million	-605,163 Reduced 24.5%	1,864,636 $404 Million
Q1 2023 May 12, 2023	BUY	$161.33 - $204.36 $10.7 Million - $13.5 Million	66,068 Added 2.75%	2,469,799 $449 Million
Q4 2022 Feb 13, 2023	BUY	$191.53 - $236.82 $28 Million - $34.6 Million	146,037 Added 6.47%	2,403,731 $472 Million

Q3 2022 Nov 14, 2022	BUY	$123.79 - $277.42 $45.9 Million - $103 Million	371,050 Added 19.67%	2,257,694 $508 Million
Q2 2022 Aug 12, 2022	BUY	$93.97 - $143.33 $24.5 Million - $37.3 Million	260,239 Added 16.0%	1,886,644 $239 Million
Q1 2022 May 12, 2022	SELL	$98.9 - $132.37 $1.21 Million - $1.62 Million	-12,212 Reduced 0.75%	1,626,405 $206 Million
Q4 2021 Feb 10, 2022	BUY	$110.64 - $159.4 $6.1 Million - $8.79 Million	55,120 Added 3.48%	1,638,617 $215 Million
Q3 2021 Nov 09, 2021	BUY	$101.2 - $125.87 $382,536 - $475,788	3,780 Added 0.24%	1,583,497 $194 Million
Q2 2021 Aug 11, 2021	BUY	$107.45 - $135.95 $170 Million - $215 Million	1,579,717 New	1,579,717 $180 Million

346K

Ticker KRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,965,000
Description
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.